[HTML][HTML] Is azvudine comparable to nirmatrelvir-ritonavir in real-world efficacy and safety for hospitalized patients with COVID-19? A retrospective cohort study
Q Zhao, B Zheng, B Han, P Feng, Z Xia, H Jiang… - Infectious Diseases and …, 2023 - Springer
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19
in China due to their earlier approval by the National Medical Products Administration …
in China due to their earlier approval by the National Medical Products Administration …
Is azvudine comparable to nirmatrelvir-ritonavir in real-world efficacy and safety for hospitalized patients with COVID-19? A retrospective cohort study.
Q Zhao, B Zheng, B Han, P Feng, Z Xia, H Jiang… - 2023 - cabidigitallibrary.org
Introduction: Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-
19 in China due to their earlier approval by the National Medical Products Administration …
19 in China due to their earlier approval by the National Medical Products Administration …
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Q Zhao, B Zheng, B Han, P Feng, Z Xia… - Infectious Diseases …, 2023 - search.proquest.com
Methods This retrospective cohort study was conducted using data collected from Tongde
Hospital of Zhejiang Province between December 2022 and January 2023. All-cause …
Hospital of Zhejiang Province between December 2022 and January 2023. All-cause …
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Q Zhao, B Zheng, B Han, P Feng… - Infectious diseases …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19
in China due to their earlier approval by the National Medical Products Administration …
in China due to their earlier approval by the National Medical Products Administration …
[HTML][HTML] Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
Q Zhao, B Zheng, B Han, P Feng, Z Xia… - Infectious Diseases …, 2023 - ncbi.nlm.nih.gov
Methods This retrospective cohort study was conducted using data collected from Tongde
Hospital of Zhejiang Province between December 2022 and January 2023. All-cause …
Hospital of Zhejiang Province between December 2022 and January 2023. All-cause …
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Q Zhao, B Zheng, B Han, P Feng, Z Xia… - … Diseases and Therapy, 2023 - go.gale.com
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19
in China due to their earlier approval by the National Medical Products Administration …
in China due to their earlier approval by the National Medical Products Administration …
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Q Zhao, B Zheng, B Han, P Feng, Z Xia… - … Diseases & Therapy, 2023 - search.ebscohost.com
Introduction: Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-
19 in China due to their earlier approval by the National Medical Products Administration …
19 in China due to their earlier approval by the National Medical Products Administration …
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Q Zhao, B Zheng, B Han, P Feng, Z Xia… - Infectious Diseases …, 2023 - europepmc.org
Methods This retrospective cohort study was conducted using data collected from Tongde
Hospital of Zhejiang Province between December 2022 and January 2023. All-cause …
Hospital of Zhejiang Province between December 2022 and January 2023. All-cause …
Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Q Zhao, B Zheng, B Han, P Feng, Z Xia… - Infectious Diseases …, 2023 - europepmc.org
Methods This retrospective cohort study was conducted using data collected from Tongde
Hospital of Zhejiang Province between December 2022 and January 2023. All-cause …
Hospital of Zhejiang Province between December 2022 and January 2023. All-cause …